Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Anne Noonan
- Study ID
- NCT04115163
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Gemcitabine — DRUGGiven IV
- Nab-paclitaxel — DRUGGiven IV
Study Details
This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may improve response in patients with pancreatic cancer.
Key Dates
- Start date
- Jun 24, 2020
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 67 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (gemcitabine, nab-paclitaxel)Patients receive gemcitabine IV over 30 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Overall response rate (ORR) [ Time Frame: Up to 2 years ]
Central Contacts
- The Ohio State University Comprehensive Cancer Center1-800-293-5066
- Danielle Trunzo
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | Anne Noonan, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Columbus, OH
By research site
Related Studies
- Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic CancerPHASE3 · Recruiting · Eleison Pharmaceuticals LLC. · Whittier, California
- LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer CachexiaRecruiting · University of Rochester · Fort Smith, Arkansas
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic AlterationsPHASE2 · Recruiting · Sameek Roychowdhury · Birmingham, Alabama
- Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic CancerPHASE3 · Recruiting · NRG Oncology · Gilbert, Arizona